openPR Logo
Press release

Global Hypertrophic Cardiomyopathy Therapeutics Market by Drug Classes, Clinical Pipeline and Forecast to 2020

03-07-2017 11:44 AM CET | Health & Medicine

Press release from: iHealthcareAnalyst, Inc.

Global Hypertrophic Cardiomyopathy Therapeutics Market

The global hypertrophic cardiomyopathy therapeutics market growing at a rate of 1.8% CAGR, is estimated to reach USD 1.2 Billion by 2020 due to higher incidence chronic cardiovascular diseases worldwide.

Browse Hypertrophic Cardiomyopathy Therapeutics Market by Drug Classes (Antiarrhythmic Agents, Anticoagulants, Beta Adrenergic Blocking Agents, and Calcium Channel Blockers) and Clinical Pipeline Analysis of Phase 1, 2 and 3 Drugs 2016-2020 at https://www.ihealthcareanalyst.com/report/hypertrophic-cardiomyopathy-therapeutics-market/

Hypertrophic cardiomyopathy (HCM) is a heterogeneous cardiac disease with a diverse clinical presentation and course. Hypertrophic cardiomyopathy occurs if heart muscle cells enlarge and cause the walls of the ventricles (usually the left ventricle) to thicken. Despite this thickening, the ventricle size often remains normal. However, the thickening may block blood flow out of the ventricle and the condition is called obstructive hypertrophic cardiomyopathy. Sudden death is most common in young patients, and death from heart failure or stroke occurs more frequently in middle and old age. HCM is also a common inherited heart disease with serious adverse outcomes, including heart failure, arrhythmias, and sudden cardiac death. Medications include beta blockers, calcium channel blockers, antiarrhythmic drugs, and anti-coagulating agents, and rarely, diltiazem, amiodarone, and disopyramide.

The global hypertrophic cardiomyopathy therapeutics market report estimates the market size (Revenue USD million - 2013 to 2020) for key market segments based on the drug classes (antiarrhythmic agents, anticoagulants, beta adrenergic blocking agents, and calcium channel blockers) and clinical pipeline analysis of phase 1, 2 and 3 drugs, and forecasts growth trends (CAGR% - 2016 to 2020). The global hypertrophic cardiomyopathy therapeutics market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global hypertrophic cardiomyopathy therapeutics market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments.

Major players operating in the global hypertrophic cardiomyopathy therapeutics market and included in this report are Pfizer, Inc., Merck & Co., Teva Pharmaceuticals Ltd., Mylan N.V., Novartis AG, and Sanofi S.A.

To request Table of Contents and Sample Pages of this report visit:
https://www.ihealthcareanalyst.com/report/hypertrophic-cardiomyopathy-therapeutics-market/

iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.

In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.

Ana Aitawa
iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Phone: (314) 500-7508
Email: sales@ihealthcareanalyst.com
https://www.ihealthcareanalyst.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Hypertrophic Cardiomyopathy Therapeutics Market by Drug Classes, Clinical Pipeline and Forecast to 2020 here

News-ID: 459082 • Views: 156

More Releases from iHealthcareAnalyst, Inc.

Global Blood Gas Monitoring Products Market Growing at CAGR of 6.2% to Reach $5. …
The global market for blood gas monitoring products is estimated to reach $5.5 billion by the end of 2025, expanding at a CAGR of 6.2% during the forecast period, supported by growing geriatric population, rising prevalence of chronic diseases, and technological advances. The global blood gas monitoring devices market research report provides market size (Revenue US$ Million 2017 to 2025), market share analysis, growth trends and forecast (CAGR%, 2019 to 2025).
Advances in Mobile Connectivity Services to Drive Telemedicine Technologies and …
According to a new market research report Telemedicine Technologies and Services Market 2015-2023 published by iHealthcareAnalyst, Inc., the global computer-aided detection market to reach US$ 73.2 Billion by 2023, expanding at a CAGR of 13.5% from 2018-2023. Visit the Global Telemedicine Technologies and Services Market Analysis and Forecast 2018-2023 report at https://www.ihealthcareanalyst.com/report/telemedicine-technologies-services-market/ The global telemedicine technologies and services market newly published (updated 2018) report estimates the market size (US$ million 2015-2023)
Global Internet Pharmacies Market to Cross US$ 100 Billion by 2023
The global internet pharmacies market is estimated to reach US$ 106 Billion by 2023, growing at a CAGR of 15.7% over the forecast period, driven by rising personal disposable income, lower prices, surge in internet penetration, stupendous growth of online retail market and a large number of online players entering the online healthcare product segment. The major players are in a race to increase their share in the industry by
Global Cerebrospinal Fluid Management Market to Reach 1.9 US$ billion by 2023 gr …
According to a new market research report (updated 2018) published by iHealthcareAnalyst, Inc., Cerebrospinal Fluid Management Market – Global CSF Products Analysis and Forecast 2018-2023, the global cerebrospinal fluid management market was valued at US$ 1,045 Million in 2013 and to reach US$ 1.9 billion by 2023, growing at a CAGR of 5.5% from 2018-2023. Visit the Global Cerebrospinal Fluid Management Market – Global Patient Solutions, System Strengthening and End Users

All 5 Releases


More Releases for Hypertrophic

Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Opportunity Analysis, 2018 …
Hypertrophic Cardiomyopathy (HCM) is a genetic condition of heart muscle associated with the thickened heart muscle wall. HCM is caused due to the changes or mutation in one or more genes, which is inherited. Hypertrophic cardiomyopathy affects the muscular wall of heart making them stiff. This thickening makes harder for the heart to pump blood out of the heart and around the body. Shortness of breath, palpitations, chest pain, and
Hypertrophic Cardiomyopathy Therapeutics Market Trends, outlook and Opportunity …
With a CAGR of 1.4% expected to be achieved between 2015 and 2023, the TMR report has prognosticated the global HCM therapeutics market to be worth a US$1.3 bn by the concluding forecast year from a US$1.2 bn in 2015. By drug class, calcium channel blockers could overpower other markets under the classification with a higher share. For the forecast timeframe 2015–2023, the calcium channel blockers market could expand at
Hypertrophic Cardiomyopathy - Pipeline Review and Industry Forecast 2017-2022
Market Research Hub's Pharmaceutical and Healthcare latest pipeline guide Hypertrophic Cardiomyopathy - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hypertrophic Cardiomyopathy (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Request
Hypertrophic Cardiomyopathy Therapeutics Market Demand and Growth by 2023
Global Hypertrophic Cardiomyopathy Therapeutics Market – Key Trends With heart diseases emerging as one of the most common causes of mortality among men and women worldwide, Transparency Market Research (TMR) expects the demand for hypertrophic cardiomyopathy (HCM) therapeutics to surge considerably. Furthermore, the market is expected to gain significant impetus from successful government interventions aimed at spreading awareness about hypertrophic cardiomyopathy. Browse the Complete Report Details for this Market at: http://www.transparencymarketresearch.com/hypertrophic-cardiomyopathy-therapeutics-market.html TMR
Global Hypertrophic Cardiomyopathy Therapeutics Market: Key vendors - Merck, Pfi …
Latest industry research report on: Global Hypertrophic Cardiomyopathy Therapeutics Market : Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts HCM is the enlargement of the heart muscle (myocardium), which disrupts the functions of the heart. HCM is mostly caused due to gene mutation and is a significant cause of sudden cardiac death in any age group. Hypertrophy is defined as an enlargement of a tissue or organ,
Hypertrophic Cardiomyopathy Therapeutics Market to Gain Significant Impetus from …
The global hypertrophic cardiomyopathy (HCM) therapeutics market is dominated by companies exhibiting high sales. However, generic manufacturers are making their presence felt in the market gradually. As per Transparency Market Research (TMR), the top three companies in the market, Sanofi S.A., Pfizer, Inc., and Merck & Co., accounted for a share of over 64.5%, which points toward a highly consolidated vendor landscape. Browse the Complete Details of this Report at: